Eli LillyLLY

NYSE · USA · Segment 1 of 8 in the Medicine, pharma & life science value chain: Diabetes & metabolic disease

American pharmaceutical group with one of the industry's strongest pipelines — GLP-1 products Mounjaro and Zepbound, alongside treatments in diabetes, oncology and neurology.

Diabetes & metabolic disease: Treatment and monitoring of diabetes and metabolic disease — from insulin to glucose monitoring.

Key metrics

Market cap

$1.1T

Price

$1,189.98

Today

−2.2%

Return YTD

+13.2%

Return 1Y

+54.6%

P/E

44.3

P/S

15.5

P/B

35.9

Data as of 2026-07-10 · updates daily after U.S. close

Theme exposure

GLP-1ObesityDiabetes exposureDiabetes

In the value chain

Products & services

GLP-1 (Mounjaro, Zepbound)
Diabetes & insulin
Oncology & neurology

Competitors

Novo Nordisk
Pfizer
Amgen

Risks

High valuation
Manufacturing capacity
Patent cliff over time

Same segment: Diabetes & metabolic disease

DexComDXCM InsuletPODD

See where Eli Lilly sits in the full Medicine, pharma & life science map — every segment from upstream suppliers to end markets, with daily metrics.Open the Life science value chain →